IQWiG investigates benefit of biomarker tests to support decision on adjuvant chemoth
 

The German Institute for Quality and Efficiency in Health Care (IQWiG) investigated the benefit of biomarker tests to support the decision for or against adjuvant systemic chemotherapy in certain breast cancer patients, that is, women with primary hormone receptor-positive, HER2-negative breast cancer and up to 3 affected lymph nodes.

More...